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Abstract
Volumetric absorptive microsampling (VAMS), an emerging microsampling technique, is expected to overcome some disad-
vantages of dried blood spots such as volume inaccuracy and influence of hematocrit (HT). This study aimed to develop and
evaluate a VAMS-based strategy for quantification of 13 frequently prescribed antipsychotics in finger prick blood within the
scope of adherence monitoring to complement already-established qualitative urine analysis. The final workflow consisted of
VAMS tip hydration and subsequent precipitation. Samples were analyzed by using reversed-phase ultra-high-performance
liquid chromatography and Orbitrap mass spectrometry operated in parallel reaction monitoring mode. The analytical procedure
was successfully validated based on international recommendations at three different HT values (20%, 40%, 60%) for most of the
analytes. Selectivity and within/between-run accuracy and precision were in accordance with the recommendations inmost cases.
Internal standard–normalized matrix factor met recommended criteria for all analytes at HT 40%. For the HT values of 20% and
60%, only four substances did not meet the criteria. Dilution integrity was given for all substances, except for olanzapine,
allowing a quantification over the whole therapeutic range of selected antipsychotics. Long-term stability in VAMS tips was
tested and revealed degradation of five antipsychotic drugs after 1 week of storage at 24 °C. A proof of concept of the
applicability of the method was obtained by quantification of a selection of the 13 antipsychotic drugs in VAMS tips and
matched plasma samples. Results were coherent between matrices. Thus, VAMS was shown to be a promising alternative for
adherence monitoring of at least the investigated antipsychotics.
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Introduction
A combination of antipsychotics and psychotherapy is often
used to treat psychotic symptoms caused for example by
schizophrenia or bipolar disorders [1, 2], but there is a wide
interpatient variability concerning the response to the therapy.
It is also well known that patients suffering from psychotic
symptoms often show low adherence to drug therapy [3–6].
Bohlken et al. came to the conclusion after reviewing a data-
base that only about 60% of schizophrenia and bipolar disor-
der patients are expected to be adherent [7]. Consequences of
non-adherence are poor or nonresponse to therapy and may
then result in an increase of disease burden, inpatient admis-
sion rate, suicide rate, and treatment costs [4, 8]. Currently,
analytical adherence monitoring is usually performed using
traditional matrices like plasma or serum obtained from ve-
nous whole blood [9–11]. However, venous whole blood sam-
pling procedure can cause discomfort and anxiety, especially
amongst the psychiatric population and can only be performed
by trained personnel. Alternative sampling methods such as
microsampling may overcome these disadvantages. One of
the most popular methods, first described in 1963, is sampling
of dried blood spots (DBS) [12]. DBS consist of small drops
of capillary blood usually with unknown volume soaked on
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filter paper [12]. The use of DBS is promoted as easy, cost-
effective, minimally invasive, and as a suitable home sam-
pling technique. DBS were used for therapeutic drug monitor-
ing (TDM) of antipsychotics amongst others [13, 14].
However, DBS have also some drawbacks like hematocrit
(HT) effects and volume inaccuracy [15]. Therefore, further
alternatives like volumetric absorptive microsampling
(VAMS) have been developed. VAMS devices consist of po-
rous hydrophilic tips attached to a plastic sample handler,
which can absorb different defined volumes of finger prick
blood (FPB) by wicking (see Supplementary Information
(ESM) Fig. S1) [16, 17]. VAMS are expected to maintain
the advantages of DBS and to overcome their limitations.
VAMS has already been used for monitoring of HbA1C
[18], in metabolomic studies [19], and for screening of plas-
ma, urine, and oral fluid for drugs of abuse [20, 21].
Furthermore, VAMS was used for TDM and determination
of pharmacokinetic parameters [22]. Recently, Stern et al.
published a method using VAMS for the quantification of
psychiatric drugs including some antipsychotics [23]. So far
and to the best of our knowledge, no research article demon-
strating the feasibility of VAMS for adherence monitoring
was published. Therefore, the aim of this study was to develop
and evaluate a VAMS-based strategy for adherence monitor-
ing of antipsychotics in FPB by using drug concentrations to
complement qualitative urine analysis [24]. Analysis should
be done by means of LC-HRMS/MS and the whole quantita-
tive workflow should be validated in accordance with interna-
tional guidelines [25, 26]. Validation included the evaluation
of an HT range from 20 to 60% and a quantitative comparison
of VAMS to plasma samples gained from matched whole
blood. The 13 most frequently prescribed antipsychotics—
amisulpride, aripiprazole, cyamemazine, clozapine, haloperi-
dol, melperone, olanzapine, paliperidone, pipamperone,
promethazine, prothipendyl, quetiapine, and risperidone—
should be included making the method suitable for adherence
monitoring as complement to urine analysis and demonstrat-
ing its potential for TDM.
Experimental
Chemicals and other materials
Quetiapine was purchased from Astra Zeneca, Macclesfield
(UK); promethazine from Bayer, Leverkusen (Germany);
paliperidone and risperidone from Janssen, Beerse
(Belgium); amisulpride, melperone, and prothipendyl from
LGC, Luckenwalde (Germany); clozapine from Novartis
Pharma, Wehr (Germany); haloperidol from Siegfried,
Säckingen (Germany); and aripiprazole, cyamemazine, and
olanzapine from Sigma-Aldrich, St. Louis (USA).
Trimipramine-d3 was purchased from LGC, Wesel
(Germany). All other chemicals (LC-MS grade or analytical
grade) were from VWR, Darmstadt (Germany). Mitra VAMS
with a 10-μL absorbing tip were purchased from Neoteryx,
Torrance (USA). Blank EDTA blood used for development
and validation of the procedure was collected from drug-free
healthy volunteers after obtaining written informed consent.
Blood samples for applicability studies were submitted to the
authors’ laboratory for regular toxicological analysis and han-
dled according to the institutional protocol and regulations
concerning data privacy and sample handling.
Calibrators, quality controls, internal standards, and
preparation of VAMS
Stock solutions of each compound were prepared at a concentra-
tion of 1 mg/mL in methanol, except for aripiprazole, olanzapine,
and prothipendyl, which were prepared in DMSO. The internal
standard (IS) solution contained 0.005 mg/mL trimipramine-d3 in
methanol. Calibrator and quality controle (QC) working solutions
were prepared in methanol (stock solution A) or DMSO (stock
solution B). The final concentration in whole blood used to load
VAMS tips is shown in Table 1. Calibrator and QC samples were
obtained by adding 10 μL of each working solution to 380 μL
blank human whole EDTA blood. For the preparation of the dif-
ferent concentrations, the spiked solution did not exceed 5% of the
total matrix volume in order not to influence the composition of
the matrix [26]. The preparation of different target HT values was
achieved by removing or adding plasma after centrifugation for
11 min at 9660×g [27, 28].
Whole blood was incubated for 30 min at 37 °C and
1500 rpm to allow plasma-protein binding and diffusion into
red blood cells. Afterwards, VAMS tips were held onto the
surface of whole blood until they turned completely red with
an additional waiting time of 2 s [16]. VAMS tips were
dried for 3 h at room temperature (24 °C) before sample
preparation [29]. Concentrations of standard solutions
used for standard addition procedure in plasma are
shown in the ESM in Table S1. All solutions were
stored at − 20 °C in amber glass vials.
VAMS sample preparation
The sample preparation was based on a method published by
D’Urso et al. with some adjustments [30]. Dried VAMS tips
were stripped into 2-mL reaction tubes. Volumes of 90 μL
purified water and 10 μL IS solution were added. Samples
were shaken for 15 min at 1500 rpm and 37 °C. Afterwards,
200 μL of acetonitrile (ACN) was added and samples were
shaken for 30 min at 1500 rpm and room temperature (24 °C)
followed by 10 min of centrifugation at 15,000×g and at
−10 °C. Finally, the supernatant was transferred into LC vials
and a volume of 20 μL was injected onto the LC-HRMS/MS
system, and analyzed as described below.
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Plasma sample preparation
Concentrations as well as addition steps used for standard
addition procedure are shown in the ESM Tables S1 and S2
and extraction was based on a slightly modified procedure
published by Montenarh et al. [31]. Briefly, 300 μL plasma
was mixed with 300 μL of Soerensen’s buffer (pH 7.4) and
20 μL IS solution and then spiked with addition solutions. For
liquid-liquid extraction, 700 μL ethylacetate:diethylether
(50:50, v/v) was added and samples were shaken for 5 min,
1500 rpm at room temperature (24 °C) before centrifugation
(5 min, 18,407×g). The supernatant was transferred to a vial
and evaporated under a gentle flow of nitrogen at 40 °C. The
remaining aqueous layer was mixed with 150 μLNaOH (1M)
and 700 μL ethylacetate:diethylether (50:50, v/v) and shaken
for 5 min at 1500 rpm at room temperature (24 °C) before
centrifugation (5 min, 18,407×g). The supernatant was trans-
ferred to the previously used vial and also evaporated under a
gentle flow of nitrogen at 40 °C. The extracts were finally
reconstituted in 100 μL of methanol and 20 μL was injected
onto the LC-HRMS/MS system as described below.
Instrumental settings
All samples were analyzed using a Thermo Fisher Scientific
(TF, Dreieich, Germany) Dionex UltiMate 3000 consisting of
a degasser, a quaternary pump, a DLW2wash system, and an
HTC PAL autosampler (CTC Analytics AG, Zwinger,
Switzerland), coupled to a TF Q-Exactive system equipped
with a heated electrospray ionization (HESI)-II source. Mass
calibration was done prior to analysis according to the manu-
facturer’s recommendations using external mass calibration.
Gradient elution was performed on a TF Accucore phenyl-
hexyl column (100 mm× 2.1 mm, 2.6-μm particle size). The
mobile phase A consisted of 2 mM aqueous ammonium for-
mate containing formic acid (0.1%, v/v, pH 3), and mobile
phase B consisted of 2 mM aqueous ammonium formate with
acetonitrile:methanol (50:50, v/v) plus formic acid (0.1%,
v/v), and water (1%, v/v). The flow rate was set at 750 μL/
min. The gradient was programmed as follows: 0–1 min from
100%A to 95%A, 1–4.2 min to 90%A, 4.2–13.5 min to 85%
A, 13.5 to 18min to 65%A, 18–19min to 1%A, 19–21.8 min
hold 1% A, 21.8 min to 25 min hold 100% A.
Chromatography was performed at 70 °C. The HESI-II source
conditions were as follows: ionization mode, positive; sheath
gas flow rate, 60 arbitrary units (AU); auxiliary gas flow rate,
10 AU; spray voltage, 4.00 kV; auxiliary gas heater tempera-
ture, 360 °C; ion transfer capillary temperature, 320 °C; and S-
lens RF level, 60.0.
Mass spectrometry was performed using parallel reaction
monitoring (PRM) with an inclusion list containing masses of
interest in defined time windows. The settings for PRM data
acquisition were as follows: resolution, 17,500; microscans, 1;
automatic gain control (AGC) target, 2e5; maximum injection
time (IT), 250 ms; scan range, m/z 170 to 930; isolation win-
dow, 2.0 m/z; HCD with stepped normalized collision energy
(NCE), 17.5, 35, and 52.5%; spectrum data type, profile. TF
Xcalibur Qual Browser software version 2.2 was used for data
handling. Precursor ion masses (m/z) used for the inclusion list
are represented in the ESM Table S3.
Method validation
The validation was performed according to published recom-
mendations including the European Medicines Agency
(EMA) Guideline on Bioanalytical Method Validation and
Table 1 Final concentrations (ng/mL) of analytes in whole blood used to load calibrator (Cal) VAMS-tips and quality control (QC) VAMS-tips as well
as weighting factors used for linear regression. LLOQ lower limit of quantification, ULOQ upper limit of quantification
Analyte Cal 1 LLOQ Cal 2 Cal 3 Cal 4 Cal 5 Cal 6 Cal 7 Cal 8 ULOQ QC low QC medium QC high Weighting
Amisulpride 50 85 100 200 400 600 800 1000 150 500 850 1/x2
Aripiprazole 50 85 100 200 400 600 800 1000 150 500 850 1/x2
Clozapine 50 85 100 200 400 600 800 1000 150 500 850 1/x2
Cyamemazine 0.5 0.85 1 2 4 6 8 10 1.5 5 8.5 1/x
Haloperidol 0.5 0.85 1 2 4 6 8 10 1.5 5 8.5 Equal
Melperone 5 8.5 10 20 40 60 80 100 15 50 85 1/x2
Olanzapine 5 8.5 10 20 40 60 80 100 15 50 85 1/x2
Paliperidone 5 8.5 10 20 40 60 80 100 15 50 85 1/x2
Pipamperone 50 85 100 200 400 600 800 1000 150 500 850 Equal
Promethazine 5 8.5 10 20 40 60 80 100 15 50 85 1/x2
Prothipendyl 0.5 0.85 1 2 4 6 8 10 1.5 5 8.5 1/x
Quetiapine 50 85 100 200 400 600 800 1000 150 500 850 1/x2
Risperidone 0.5 0.85 1 2 4 6 8 10 1.5 5 8.5 1/x2
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the International Association of Therapeutic Drug Monitoring
and Clinical Toxicology (IATDMCT) guideline for develop-
ment and validation of dried blood spot–based methods for
therapeutic drug monitoring [25, 26]. The statistical evalua-
tion of the peak area ratios of analytes versus IS was per-
formed using Microsoft Excel version 16 (Microsoft,
Redmond, USA) and TF Xcalibur Quan Browser version 2.2.
For selectivity testing, 13 blank matrices from individual
donors were analyzed in PRM mode for possible peak inter-
ferences of analytes or IS. These were divided in 10 drug-free
FPB donors and three samples were loaded with EDTA
blood–containing drugs but no antipsychotics. For carry-
over testing, a blank matrix sample was injected after analysis
of the highest calibrator (n = 3). Interfering signals of analytes
in blank matrix should be less than 20% of the lower limit of
quantification (LLOQ) and less than 5% of the IS for selec-
tivity and carry-over testing.
Three calibration ranges were defined consisting of eight
calibration points, each. Calibrators were prepared by spiking
blank matrix with different calibrator solutions (final matrix
concentrations; see Table 1). Extraction was performed as
described before. All LLOQ and upper limits of quantification
(ULOQ) are shown in Table 1. Different weighting factors
(equal, 1/x, or 1/x2) for linear regression were tested by fitting
three curves of each analyte. The suitability of the models was
evaluated using the square sum of residuals (SSR) by choos-
ing the model with the lowest SSR. All calculations were
performed using KNIME (www.knime.org) and R snippets
(www.r-projects.org). Back-calculated concentrations of
calibrators should be within ± 15% of the nominal value
(LLOQ ± 20%). If criteria are not met, the calibration standard
should be rejected for regression analysis. At least 75% of the
calibration standards must fulfill criteria.
Accuracy and precision of the quantification results were
determined for the LLOQ, QC low, QCmedium, and QC high
levels listed in Table 2. Therefore, QC samples were spiked
with separately prepared stock solutions from calibration stan-
dards. QC sample concentrations were back-calculated via the
calibration curves and compared with their nominal values.
The evaluation was performed for values of five sample rep-
licates obtained within a single run (within-run accuracy
and precision) and in three different runs (between-run
accuracy and precision). For positive assessment of ac-
curacy, mean concentrations should be within ± 15% of
the nominal values (± 20% for LLOQ). For a positive
assessment of precision, the coefficient of variation
(CV) should be within 15% (20% for LLOQ).
Dilution integrity of the final extract was determined by
spiking blank samples (n = 5) at 2.5 times higher than the
highest calibrator. Extracts were diluted 1:5 with IS-spiked
ACN or processed blank matrix containing IS [26]. Since
prothipendyl shows a broad therapeutic range (ESM
Table S4), two additional dilution factors were tested for this
analyte. An extracted sample stemming from a blood concen-
tration of 100 ng/mL prothipendyl was diluted 1:10 and 1:20
with either IS-spiked ACN or processed blank matrix contain-
ing IS. All samples were analyzed, and accuracy and precision
were determined.
Table 2 Within- and between-day accuracy (A) and precision (P) of the
LLOQ, QC low, QC medium, and QC high. Dilution integrity with ace-
tonitrile containing IS (ACN) or with processed blank matrix containing
IS (matrix). 1:5 dilution of a 2.5 higher concentration than the highest
calibrator. LLOQ lower limit of quantification, QC quality control, IS
internal standard; mid medium
Analyte Relative mean concentration (A), % (CV (P), %)
Within-day Between-day Dil 1:5
LLOQ QC low QC mid QC high LLOQ QC low QC mid QC high ACN Matrix
Amisulpride 106 (8) 102 (8) 93 (6) 107 (7) 105 (8) 102 (11) 95 (6) 104 (11) 69 (9) 99 (5)
Aripiprazole 100 (2) 100 (9) 109 (5) 97 (4) 99 (10) 106 (8) 105 (5) 100 (8) 67 (7) 105 (7)
Clozapine 97 (8) 107 (8) 102 (6) 115 (6) 100 (6) 106 (7) 103 (5) 111 (8) 77 (7) 115 (4)
Cyamemazine 90 (13) 95 (9) 88 (7) 90 (7) 115 (27) 87 (17) 84 (7) 90 (9) 56 (12) 90 (7)
Haloperidol 105 (15) 95 (9) 100 (5) 103 (5) 106 (17) 101 (12) 98 (7) 104 (11) 80 (12) 106 (9)
Melperone 107 (4) 101 (8) 96 (7) 98 (7) 97 (10) 96 (9) 95 (6) 101 (10) 61 (9) 89 (7)
Olanzapine 89 (14) 101 (11) 98 (6) 100 (2) 92 (11) 98 (11) 99 (6) 101 (10) 38 (13) 50 (12)
Paliperidone 96 (8) 110 (13) 102 (8) 109 (5) 102 (9) 109 (11) 104 (6) 109 (10) 71 (8) 107 (4)
Pipamperone 96 (7) 113 (11) 100 (6) 111 (7) 99 (7) 111 (9) 106 (7) 110 (9) 65 (8) 110 (3)
Promethazine 97 (8) 104 (4) 97 (6) 104 (9) 101 (11) 102 (7) 96 (6) 105 (10) 65 (11) 97 (8)
Prothipendyl 120 (10) 97 (12) 102 (9) 100 (9) 111 (38) 98 (12) 106 (9) 103 (10) 70 (13) 104 (8)
Quetiapine 101 (3) 105 (10) 96 (4) 105 (3) 108 (14) 106 (10) 100 (6) 106 (12) 72 (6) 110 (4)
Risperidone 98 (15) 95 (8) 86 (2) 91 (4) 103 (12) 97 (11) 89 (5) 96 (11) 64 (7) 94 (4)
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The matrix factor (MF) and the recovery (RE) were inves-
tigated at low and high QC levels for six blank matrix samples
of individual donors. VAMS tips were prepared with whole
blood (EDTA) of HT 40%. Additionally, three blank matrix
samples of individual donors were prepared at HT 20% and
HT 60% each. The MF was calculated by the ratio of the peak
area in the presence of matrix (blank matrix spiked after ex-
traction) to the peak area in the absence ofmatrix (pure analyte
solution). The IS-normalized MF was calculated by dividing
the MF of the analytes by the MF of the IS. The RE was
calculated by the ratio of the peak area extracted with
the matrix (blank matrix spiked before extraction) to the
peak area in the presence of matrix (blank matrix spiked
after extraction). The CV of the IS-normalized MF and
the RE should be within 15%.
The stability of the stock solutions A and B was tested over
a time of 10 weeks (n = 3). Furthermore, autosampler stability
(24 h, 10 °C) of processed samples and long-term stability (1
and 2 weeks, 24 °C) in the test device were investigated (n = 4)
using the low and high QC levels. Deviations between obtain-
ed and nominal concentrations of QCs should be within ±
15% when analyzed immediately after preparation and after
evaluated storage conditions using a freshly prepared calibra-
tion curve.
Proof of concept
Matched human plasma samples and VAMS tips soaked with
EDTA blood of 10 individuals were analyzed. All samples
were submitted to the authors’ laboratory for regular toxico-
logical analysis.
Results and discussion
Assessing adherence based on serum drug concentrations to
complement urine analysis is expected to be more accurate
than urine analysis alone, particularly when using the so-
called dose-related concentration approach as proposed, e.g.,
by Ritscher et al. [24]. In general, drugs with low bioavailabil-
ity, low renal excretion, or underlying extensive metabolism
may be underestimated concerning their adherence when
using qualitative urine analysis alone. Therefore, we aimed
to develop a strategy for the simultaneous quantification of
the 13 most frequently prescribed antipsychotics in FPB using
VAMS with a particular focus on adherence monitoring.
Paliperidone (9-hydroxyrisperidone) can be prescribed as a
drug but is also the active metabolite of risperidone.
Aripiprazole, clozapine, and quetiapine also have active me-
tabolites; however, none of them can be prescribed as a drug
itself. For a correct assessment of adherence, the quantifica-
tion of active metabolites is not necessary. However, this
might be a limitation point if the method is used for TDM.
Figures S2 and S3 (ESM) show the chromatographic sep-
aration of the antipsychotics at the LLOQ level and in a patient
sample within 20 min, respectively. The long run time of
20 min (including the equilibration step of then in total
25 min) was acceptable as the method could be integrated into
our laboratory routine. The aim was to achieve sufficient sep-
aration without changing the column type or composition of
mobile phases and to retain the standard setup. Furthermore,
adherence monitoring is normally no urgent analysis, and
therefore a total runtime of 25 min was acceptable. An injec-
tion volume of 20 μL was chosen since it provided better
sensitivity compared to a volume of 10 μL. This in turn led
to peak-decompression, which was tolerated and had no neg-
ative impact on analytical results. For identification, full MS2-
spectra were compared to a database [32] and the peak area
ratios of the analyte-specific fragment ion in MS2 (ESM
Table S3) and those of the IS were used for quantification.
For analysis of human samples, each analytical batch
consisted of a zero-sample containing IS but no antipsy-
chotics, eight calibration standards, three QC levels, and the
patient samples.
The IS trimipramine-d3 did not coelute with the analytes.
No interfering signals from endogenous compounds or other
drugs (listed in ESM Table S5) as well as no IS carry-over
could be observed. However, carry-over was occasionally ob-
served for cyamemazine, haloperidol, and olanzapine espe-
cially after injection of concentrations above the thera-
peutic range. Hence, samples following a high concen-
tration of those drugs should be reanalyzed after a
washing run with extracted blank matrix.
A linear calibration model could be used for all analytes
after testing different weighting factors (equal, 1/x, 1/x2; see
Table 1). Results for the within- and between-day accuracy
and precision are shown in Table 2. For the within-day accu-
racy, all analytes had a mean concentration within ± 15%
(LLOQ ± 20%) of the nominal concentration and the within-
day precision did not exceed a CV of 15%. However, for
between-day accuracy and precision, cyamemazine only met
required validation parameters at the high QC level and
prothipendyl exceeded precision at the LLOQ. Anyhow, the
lowest therapeutic concentration of prothipendyl is already
covered by the QC low level. Consequently, the QC low level
should be used as cutoff concentration for the quantification of
prothipendyl. Cyamemazine failed the validation in this assay.
Dilution integrity was tested by dilution (1:5) of a proc-
essed sample, having a concentration 2.5 times higher than
the highest calibrator, either with IS-spiked ACN
(trimipramine-d3, 0.166 mg/L) or with processed blank matrix
containing IS. Using IS-spiked ACN for dilution, none of the
analytes passed validation. However, if the final extract was
diluted with processed blank matrix containing IS, all analytes
passed validation except olanzapine. Anyway, the therapeutic
range of olanzapine is completely covered by the calibration
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range. For prothipendyl, two additional dilution factors
(1:10 and 1:20) were tested. Again, validation parame-
ters were only fulfilled when processed blank matrix
containing IS was used (see ESM Table S6).
Determined IS-normalized MFs and CVs are given in
Table 3. At different HT values, MFs varied between 0.77
and 1.28. However, these effects were found to be reproduc-
ible with CVs within 15% except for haloperidol (QC low HT
20% and HT 60%), olanzapine (QC low and high HT 60%),
and prothipendyl (QC low HT 20% and HT 60%). Thus, the
MF was reproducible for all analytes at HT 40%. Higher
CVs at HT 20% and HT 60% for haloperidol,
olanzapine, and prothipendyl should not play a role for
normal HT fluctuation of healthy patients.
RE values of the analytes of low and high QC in VAMS
tips at different HT values are summarized in Table 3. The RE
was found to be reproducible, even at low HT values, with
CVs within 15% except for cyamemazine (QC low HT 60%),
olanzapine (QC low HT 40% and HT 60%; QC high HT
40%), and prothipendyl (QC low HT 20%). However, CVs
never exceeded 21%. Only for a few antipsychotics, the nom-
inal RE value at HT 20% and 60% differed from the HT 40%
value bymore than 15%. Greater nominal RE deviations at the
low HT values were observed for amisulpride (QC high HT
20%), haloperidol (QC low HT 20% and QC high HT 60%),
paliperidone (QC low HT 20%), prothipendyl (QC low HT
20%), and risperidone (QC low HT 60%). Only in the case of
haloperidol (21%) and prothipendyl (30%), nominal RE devi-
ation exceeded 20%. In summary, the present method allowed
the quantification of amisulpride, aripiprazole, clozapine,
haloperidol, melperone, olanzapine, paliperidone,
pipamperone, promethazine, prothipendyl, quetiapine, and
risperidone over their complete therapeutic range (ESM
Table S4) in whole blood (HT 40%) using VAMS devices.
For prothipendyl, concentration exceeding the QC high
can be quantified since dilution integrity was given for
three dilution factors. Only cyamemazine failed valida-
tion in between-day accuracy and precision.
Stock solutions were stable over 10 weeks at −20 °C in
amber glass vials. Results of short- and long-term stability
are given in ESM Table S7. After storage of processed sam-
ples in the autosampler for 24 h at 10 °C, no analyte showed a
degradation over 15% of the nominal concentration for the
low and high QC levels. This is of advantage if long-lasting
analytical series are planned. However, autosampler stability
can only be guaranteed for 24 h, based on these experiments.
Hence, the duration of a batch should not exceed this period of
time. However, not all analytes are long-term stable in the
device. After 1-week storage at 24 °C, cyamemazine,
melperone, olanzapine, promethazine, and prothipendyl
showed degradation over 15% of nominal concentration.
Haloperidol was stable for 1 week and amisulpride,
aripiprazole, clozapine, paliperidone, pipamperone,
quetiapine, and risperidone were stable for 2 weeks in the
sample device at 24 °C. The instability of olanzapine and
promethazine in whole blood at 20 °C was already described
but melperone was stable over 10 weeks at 20 °C in whole
blood [33]. Good stability of amisulpride, aripiprazole, cloza-
pine, haloperidol, paliperidone, pipamperone, quetiapine, and
risperidone was already described for DBS [14, 34, 35]. Proof
Table 3 Internal standard (IS)–normalized matrix factors (MF), recovery (RE), and coefficients of variation (CVs) of the analytes of low- and high-
quality controls (QC) for VAMS at different hematocrit (HT) values (n = 6 at HT 40%; n=3 at HT 20% and HT 60%)
Analyte IS-normalized MF (CV, %) RE, % (CV, %)
QC low QC high QC low QC high
HT 20% HT 40% HT 60% HT 20% HT 40% HT 60% HT 20% HT 40% HT 60% HT 20% HT 40% HT 60%
Amisulpride 0.85 (7) 0.84 (6) 0.98 (7) 0.83 (7) 0.86 (7) 0.87 (10) 138 (8) 123 (6) 132 (13) 146 (7) 130 (4) 132 (3)
Aripiprazole 0.97 (5) 1.02 (8) 1.15 (2) 1.05 (4) 1.05 (8) 1.08 (10) 131 (8) 123 (8) 117 (4) 128 (4) 118 (5) 110 (6)
Clozapine 0.95 (6) 0.92 (6) 1.06 (4) 0.91 (5) 0.91 (6) 0.95 (9) 111 (5) 114 (9) 109 (3) 117 (4) 105 (7) 102 (6)
Cyamemazine 1.24 (9) 1.28 (12) 1.26 (1) 1.14 (8) 1.09 (8) 1.10 (6) 49 (13) 52 (10) 63 (18) 68 (9) 68 (8) 58 (4)
Haloperidol 0.94 (20) 0.99 (14) 1.08 (33) 0.93 (8) 0.95 (3) 0.92 (5) 71 (2) 93 (12) 103 (14) 80 (12) 75 (13) 91 (7)
Melperone 0.85 (4) 0.85 (5) 0.95 (6) 0.89 (7) 0.89 (5) 0.94 (8) 63 (15) 67 (11) 65 (15) 54 (10) 60 (11) 61 (6)
Olanzapine 0.77 (10) 0.81 (10) 0.93 (20) 0.86 (7) 0.85 (7) 0.94 (17) 26 (5) 13 (18) 16 (21) 34 (15) 26 (18) 20 (14)
Paliperidone 0.88 (6) 0.87 (7) 1.04 (12) 0.90 (4) 0.91 (5) 0.95 (11) 112 (3) 132 (9) 138 (12) 136 (3) 126 (8) 123 (8)
Pipamperone 0.99 (4) 1.00 (5) 1.12 (4) 0.99 (7) 0.98 (6) 1.01 (9) 114 (8) 114 (7) 123 (8) 115 (3) 115 (4) 112 (5)
Promethazine 0.92 (5) 0.92 (6) 1.01 (8) 0.97 (4) 0.96 (5) 1.02 (9) 60 (12) 57 (14) 56 (11) 59 (6) 55 (7) 52 (7)
Prothipendyl 0.96 (18) 1.10 (14) 1.06 (22) 0.96 (4) 0.91 (11) 0.99 (6) 32 (20) 62 (16) 63 (4) 45 (9) 46 (15) 39 (6)
Quetiapine 0.88 (1) 0.90 (5) 1.00 (3) 0.91 (8) 0.91 (8) 0.93 (7) 146 (7) 139 (8) 137 (3) 143 (4) 133 (4) 129 (4)
Risperidone 0.85 (3) 0.85 (5) 0.91 (7) 0.85 (7) 0.89 (6) 0.91 (9) 116 (14) 107 (6) 125 (3) 123 (5) 117 (11) 114 (5)
1734 Jacobs C.M. et al.
of concept of the presented method was achieved using 10
matched human whole blood (EDTA)–loaded VAMS tips
and plasma samples. Unfortunately, samples containing
aripiprazole, cyamemazine, haloperidol, and prothipendyl
were not available for further evaluation.
Table 4 shows the results after analyzing VAMS tips and
plasma and the assessment of adherence in both matrices. For
a positive assessment of adherence, the minimal concentration
in blood should be above the lowest published therapeutic
concentration with a tolerance limit of ± 15% to take measure-
ment inaccuracy into account. Adherence assessment differed
between VAMS and plasma only once. This could be ex-
plained by the measurement inaccuracy within ± 15% regard-
ing plasma. In three cases, quantification revealed concentra-
tions above the therapeutic range but it is known that high
doses of antipsychotics are used for treatment [36, 37].
Results also showed that VAMS can be a promising tool for
adherence monitoring and that the developed VAMS strategy
is consistent with findings in plasma.
Since the method was fully validated and meets certain
requirements such as a full calibration within therapeutic
ranges of the antipsychotics, it might also be used for TDM.
However, before using this method for TDM purpose, some
more data are needed. The therapeutic ranges given in ESM
Table S4 are plasma concentrations and the relationship be-
tween plasma and whole blood concentrations has to be
established first. Patteet et al. calculated whole blood thera-
peutic ranges using blood to serum ratios and conducted a
clinical study to make a comparison between antipsychotic
concentrations found in venous whole blood and capillary
DBS samples. They came to the result that the clinical inter-
pretation, for the tested antipsychotics, of serum, whole blood,
and DBS concentrations was identical [38]. Stern et al. also
compared capillary blood, whole blood, and plasma concen-
trations of psychiatric drugs and came to the result that the
three matrices showed a good correlation between determined
concentrations [23]. However, exact concentrations including
converting factors are not required for the assessment of ad-
herence, which was the aim of the current study.
Conclusions
A VAMS- and LC-HRMS/MS-based workflow for simulta-
neous quantification of 13 antipsychotics was successfully
developed and validated. Only 10 μL of blood was required
and the straightforward sample preparation was followed by a
complete chromatographic separation. Proof of concept was
demonstrated by quantification of 17 intakes of antipsychotics
in VAMS tips and matched plasma samples of patients.
VAMS as a sampling strategy for dried matrix was able
to overcome the hematocrit issue in most cases but the
advantage of stability in dried matrix could only be
proven for half of the analytes.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s00216-020-03143-0.
Table 4 Quantification of
antipsychotics (ng/mL) using
VAMS tips and plasma as sample











Amisulpride 209 Adherent 216 Adherent
Clozapine 400 Adherent 368 Adherent
Olanzapine 93* Adherent 98* Adherent
Olanzapine 64 Adherent 72 Adherent
Paliperidone <5 Non-adherent 6 Non-adherent
Paliperidone 12 Non-adherent 12 Non-adherent
Pipamperone 75 Non-adherent 115 Adherent
Pipamperone 450* Adherent 505* Adherent
Pipamperone <50 Non-adherent 58 Non-adherent
Pipamperone <50 Non-adherent 15 Non-adherent
Promethazine 18 Adherent 10 Adherent
Promethazine 36 Adherent 39 Adherent
Quetiapine <50 Non-adherent 8 Non-adherent
Quetiapine <50 Non-adherent 94 Non-adherent
Quetiapine 952* Adherent 1082* Adherent
Risperidone 5 Adherent 10 Adherent
Risperidone 5 Adherent 5 Adherent
*Above the therapeutic range
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